Cardiff Oncology (CRDF) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Telomir Pharmaceuticals (TELO) has outperformed Cardiff Oncology (CRDF) over the past year, losing 42.0% versus a loss of 54.6%. Cardiff Oncology is the larger company by market cap ($84.0 million vs $82.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | TELO |
|---|---|---|
| Share price | $1.08 | $1.12 |
| Market cap | $84.02M | $82.45M |
| 1-day change | +1.89% | -2.61% |
| YTD return | -61.57% | -15.79% |
| 1-year return | -54.62% | -41.97% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $1.75 |
| 52-week low | $0.76 | $0.888 |
| Distance from 52-week high | -67.37% | -36.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +257.14% |
| Average volume | 1.04M | 98.53K |
| Shares outstanding | 77.80M | 73.62M |
| Employees | 30 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TELO has outperformed CRDF by 12.7 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
CRDF vs TELO FAQ
Which is bigger, Cardiff Oncology or Telomir Pharmaceuticals?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $82.45M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, CRDF or TELO?
TELO returned -41.97% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Telomir Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiff Oncology and Biotechnology: Pharmaceutical Preparations for Telomir Pharmaceuticals.